MXCT vs TROW · rev $38.6M vs P/E 12, rev $7.09B
MaxCyte Inc (MXCT) versus T. Rowe Price Group Inc (TROW) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
T. Rowe Price Group Inc (TROW) is a asset management company listed on NASDAQ.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported TROW revenue for 2024-12-31 was $7.09B. Net income was $2.14B. Revenue was up 9.8% from 2023-12-31 to 2024-12-31. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
MXCT currently screens at market cap $124.3M. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
Not investment advice. Open the MXCT and TROW stock pages for the full models.
Not investment advice.